Vincanol is an alkaloid derived from vinca. The drug possesses hypotensive and vasodilating properties which justify its use in cardiovascular therapy. In vitro studies in rats demonstrated that vincanol may act by blocking voltage-gated Na+ channels.

Cibinetide (ARA 290; helix B surface peptide) is a novel potent and selective peptide agonist of innate repair receptor (IRR) with anti-inflammatory and tissue-protective activities. IRR activation promotes tissue protection and repair in a wide variety of preclinical models, including diabetic wound healing, diabetic neuropathy, and ischemic retinopathy. In a mouse model of diabetic small nerve fiber loss, daily administration of Cibinetide reversed neuronal dystrophy. Cibinetide administration significantly improved re-epithelization, angiogenesis, and wound healing strength in a mouse model of diabetic wounds. In clinical studies, Cibinetide administration has shown significantly increased small nerve fiber abundance, reduced neuropathic symptoms and promoted nerve fiber repair in patients with sarcoidosis or diabetes-related nerve fiber loss.